Ghost Tree Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Ghost Tree Capital’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,000	Closed	-$685K	–	74
2024 Q2	$685K	Buy	+10,000	New	+$694K	0.21%	56
2022 Q4	–	Sell	-60,000	Closed	-$2.79M	–	46
2022 Q3	$2.79M	Buy	+60,000	New	+$3.13M	0.78%	33
2017 Q3	–	Sell	-200,000	Closed	-$2.48M	–	75
2017 Q2	$2.48M	Buy	200,000 +50,000	+33%	+$580K	0.52%	57
2017 Q1	$2.44M	Buy	+150,000	New	+$2.17M	0.45%	52
2016 Q3	–	Sell	-120,000	Closed	-$4.66M	–	98
2016 Q2	$4.66M	Buy	+120,000	New	+$4.31M	1.35%	30

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ghost Tree Capital's ITCI Position: Q3 2024 in Review

Ghost Tree Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 10,000 shares — an estimated $685K sold.

Ghost Tree Capital first reported a position in ITCI in Q2 2016 and held it in 5 quarters. The position peaked at $4.66M in Q2 2016. 354 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

Ghost Tree Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
Ghost Tree Capital sold 10,000 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $685K.
Ghost Tree Capital first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and held it in 5 quarters.
Ghost Tree Capital's Intra-Cellular Therapies Inc. position peaked at $4.66M in Q2 2016.
354 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.